natgillin/translations-raw huggingface dataset:
In the extension study, similar numbers of patients taking Fosavance 70 mg/2,800 IU and Fosavance 70 mg/5,600 IU had low vitamin D levels (below 6%), but the patients taking Fosavance 70 mg/5,600 IU had greater increases in vitamin D levels over the 24 weeks of the study.
V podaljšani študiji je bilo število bolnic z nizkimi ravnmi vitamina D (pod 6 %) v skupini bolnic, ki so jemale zdravilo Fosavance 70 mg/2 800 i.e., podobno številu bolnic v skupini, ki je prejemala zdravilo Fosavance 70 mg/5 600 i.e., vendar pa so se pri bolnicah, ki so jemale zdravilo Fosavance 70 mg/5 600 i.e., v 24 tednih študije ravni vitamina D bolj povečale.
Patients should also take calcium supplements if they are not getting enough calcium from their diet. For more information, see the package leaflet.
Jemati morajo tudi dodatke kalcija, če njegov vnos s prehrano ni zadosten.
What is Fosavance used for?
Za kaj se zdravilo Fosavance uporablja?
How has Fosavance been studied?
Kako je bilo zdravilo Fosavance raziskano?
How is Fosavance used?
Kako se zdravilo Fosavance uporablja?
What is Fosavance?
Kaj je zdravilo Fosavance?
How does Fosavance work?
Kako zdravilo Fosavance deluje?
After 15 weeks, fewer patients had low vitamin D levels when they took Fosavance 70 mg/2,800 IU (11%) than when they took alendronic acid only (32%).
Dodatne študije so pokazale, da lahko vključitev vitamina D3 in alendronske kisline v isto tableto poveča ravni vitamina D. Po 15 tednih zdravljenja je bil delež bolnic z nizko ravnijo vitamina D med bolnicami, zdravljenimi z zdravilom Fosavance 70 mg/2 800 i.e., nižji (11 %) kot pri tistih, ki so prejemale le alendronsko kislino (32 %).
the dose should be reduced gradually, over at least a week.
mora nižanje odmerka potekati postopno in trajati najmanj en teden.
is available as capsules (25, 50, 75, 100, 150, 200, 225 and 300 mg) and can only be obtained with a prescription.
je na voljo v obliki kapsul (25, 50, 75, 100, 150, 200, 225 in 300 mg).
The maximum dose is 600 mg per day.
Največji odmerek je 600 mg na dan.
is a medicine used to treat adults with the following conditions:
je zdravilo, ki se uporablja za zdravljenje odraslih z naslednjimi boleznimi:
This reduces the activity of nerve cells in the brain and spinal cord that are involved in pain, epilepsy and anxiety.
S tem se zmanjša dejavnost živčnih celic v možganih in hrbtenjači, ki so povezane z bolečino, epilepsijo in tesnobo.
contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Lyrica.
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot „referenčno zdravilo“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilo Lyrica.
is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaka kot pri referenčnem zdravilu.
Doctors may choose lower doses in patients with kidney problems.
Zdravniki lahko zmanjšajo odmerek pri bolnikih s težavami z ledvicami.
The active substance in Pregabalin Zentiva k.s., pregabalin, is similar in structure to the body's own ‘neurotransmitter' gamma‑amino butyric acid (GABA), but has very different biological effects.
Zdravilna učinkovina v zdravilu Pregabalin Zentiva k.s., pregabalin, ima podobno strukturo kot telesu lastni živčni prenašalec („nevrotransmitor“) gama-aminomaslena kislina (GABA), vendar pa ima bistveno drugačne biološke učinke.
Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Lyrica, and do not need to be repeated for Pregabalin Zentiva k.s.
Študije o koristih in tveganjih zdravilne učinkovine pri dovoljenih načinih uporabe so že bile izvedene z referenčnim zdravilom Lyrica, zato jih ni treba ponoviti za zdravilo Pregabalin Zentiva k.s.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pregabalin Zentiva k.s.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pregabalin Zentiva k.s.
• neuropathic pain (pain due to nerve damage), including peripheral neuropathic pain, such as the pain experienced by patients with herpes zoster (shingles) or nerve disorders caused by diabetes,
• nevropatsko bolečino (bolečino zaradi poškodbe živcev), vključno s periferno nevropatsko bolečino, kot se pojavlja pri bolnikih, ki imajo herpes zoster (pasovec) ali motnje živčevja, ki jih povzroča diabetes, in centralno nevropatsko bolečino, kot se pojavlja pri bolnikih s poškodbo hrbtenjače;
This is a summary of the European public assessment report (EPAR) for Pregabalin Zentiva k.s.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pregabalin Zentiva k.s.
As for every medicine, the company provided studies on the quality of Pregabalin Zentiva k.s.
Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti zdravila Pregabalin Zentiva k.s.
What measures are being taken to ensure the safe and effective use of Pregabalin Zentiva k.s.
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pregabalin Zentiva k.s.
(epileptic fits starting in one specific part of the brain) that cannot be controlled with their current treatment;
• epilepsijo, pri čemer se uporablja kot „dodatek“ obstoječemu zdravljenju pri bolnikih s parcialnimi napadi (epileptičnimi napadi, ki se začnejo v določenem delu možganov), ki jih ni mogoče nadzorovati s trenutnim zdravljenjem;
For more information about treatment with Pregabalin Zentiva k.s., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
has been shown to have comparable quality and to be bioequivalent to Lyrica.
primerljivo raven kakovosti kot zdravilo Lyrica ter da mu je biološko enakovredno.
What are the benefits and risks of Pregabalin Zentiva k.s.
Kakšne so koristi in tveganja, povezani z zdravilom Pregabalin Zentiva k.s.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pregabalin Zentiva k.s.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pregabalin Zentiva k.s.
For practical information about using Pregabalin Zentiva k.s., patients should read the package leaflet or contact their doctor or pharmacist.
naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
When stopping treatment with Pregabalin Zentiva k.s.
Pri prenehanju zdravljenja z zdravilom Pregabalin Zentiva k.s.
contains the active substance pregabalin.
vsebuje zdravilno učinkovino pregabalin.
Other information about Pregabalin Zentiva k.s.
Druge informacije o zdravilu Pregabalin Zentiva k.s.
The Committee recommended that Pregabalin Zentiva k.s.
Priporočil je, da se zdravilo Pregabalin Zentiva k.s.
It is not intended to provide practical advice on how to use Pregabalin Zentiva k.s.
Za praktične informacije o uporabi zdravila Pregabalin Zentiva k.s.
Why is Pregabalin Zentiva k.s.
Zakaj je bilo zdravilo Pregabalin Zentiva k.s.
What is Pregabalin Zentiva k.s.
Kaj je zdravilo Pregabalin Zentiva k.s.
The full EPAR for Pregabalin Zentiva k.s.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Pregabalin Zentiva k.s.
Because Pregabalin Zentiva k.s.
Ker je zdravilo Pregabalin Zentiva k.s.
How has Pregabalin Zentiva k.s.
Kako se zdravilo Pregabalin Zentiva k.s.
To reduce administrative work, all response documents should be submitted as a single data package one year after the issue of the EC decision.
Zaradi zmanjšanja administrativnega dela se morajo vsi odgovori predložiti v obliki enega podatkovnega paketa v enem letu po izdaji odločitve Evropske komisije.
The MAH commits to respond to a number of unresolved quality related issues by presenting relevant and adequate documents and data as outlined in the Letter of Undertaking dated 9 December 2009.
Imetnik dovoljenja za promet z zdravilom se zavezuje, da bo odgovoril na številna nerešena vprašanja glede kakovosti s predložitvijo ustreznih in zadostnih dokumentov ter podatkov, kakor je predvideno v pismu o zavezi z dne 9. decembra 2009.
The National Competent Authorities, coordinated by the Reference Member State, shall ensure that the following conditions are fulfilled by the Marketing Authorisation Holders:
Pristojni nacionalni organi, ki jih usklajuje referenčna država članica, naj zagotovijo, da imetniki dovoljenja za promet z zdravilom izpolnijo naslednje pogoje:
This summary was last updated in April 2016.
Povzetek je bil nazadnje posodobljen aprila 2016.
The full EPAR for Clynav can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila Clynav je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
In the future, if the fish are exposed to the virus, the immune system will be able to respond more quickly.
Ob ponovni izpostavitvi ribe virusu v prihodnosti se bo imunski sistem tako hitreje odzval.
Direct contact should be avoided and protective equipment (for example protective gloves) should be worn when handling the medicine.
Treba se je izogibati neposrednemu stiku in med ravnanjem z zdravilom uporabljati zaščitno opremo (na primer zaščitne rokavice).
This is a summary of the European public assessment report (EPAR) for Clynav.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Clynav.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Clynav's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Clynav večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
The time for protection to develop following vaccination depends on the water temperature: protection starts within 399 degree days, calculated as mean water temperature in °C multiplied by number of days, for example 40 days at a water temperature of 10 °C.
Čas do razvoja zaščite po cepljenju je odvisen od temperature vode: zaščita nastopi po 399 dnevnih stopinjah, kar se izračuna kot povprečna temperatura vode v °C, pomnožena s številom dni, na primer 40 dni pri temperaturi vode 10 °C.
Needle injuries at the site of injection are common following vaccination and can persist for at least 90 days.
Poškodbe zaradi vboda z iglo na mestu injiciranja so po cepljenju pogoste in lahko trajajo najmanj 90 dni.
The most common side effects with Clynav (which may affect more than 1 in 10 fish) are short lived changes in swimming behaviour for up to two days, altered pigmentation (colouration) for up to seven days and lack of appetite for up to nine days.
Najpogostejši neželeni učinki zdravila Clynav (ki se lahko pojavijo pri več kot 1 ribi od 10) so prehodne spremembe v načinu plavanja, ki trajajo do dva dni, spremenjena pigmentacija (obarvanje), ki traja do sedem dni, in pomanjkanje apetita, ki traja do devet dni.
The vaccine is given to anaesthetised fish as a single injection into epaxial muscle (muscle of the upper half of the fish) in the area to the front and side of the dorsal fin.
Cepivo se daje anesteziranim ribam v obliki enkratne injekcije v epaksialno mišico (mišico na zgornji polovici ribe) v predel pred hrbtno plavutjo in ob njej.
The withdrawal period for fish from Atlantic salmon treated with Clynav is ‘zero' days, which means there is no mandatory waiting time.
Karenca za atlantske losose, zdravljene z zdravilom Clynav, je nič dni, kar pomeni, da ni obvezne čakalne dobe.
What are the risks associated with Clynav?
Kakšna tveganja so povezana z zdravilom Clynav?
Clynav is a DNA vaccine.
Zdravilo Clynav je DNK-cepivo.
Following artificial infection by co-habitation with infected salmon 29 days and 3 months after vaccination, fish vaccinated with Clynav had improved weight gain, reduced heart, pancreas and skeletal muscle lesions and reduced risk of death compared to fish injected with the dummy saline injection.
Po umetni okužbi s sobivanjem z okuženimi lososi 29 dni in 3 mesece po cepljenju so imele ribe, cepljene z zdravilom Clynav, boljši prirast telesne mase, manj lezij na srcu, trebušni slinavki in skeletnih mišicah ter manjše tveganje za smrt v primerjavi z ribami, ki so prejele injekcijo fiziološke raztopine brez zdravilne učinkovine.
Other information about Clynav:
Druge informacije o zdravilu Clynav
Pancreas disease in Atlantic salmon can lead to impaired daily weight gain, lesions of the heart, pancreas and skeletal muscle as well as death.
Bolezen trebušne slinavke pri atlantskem lososu lahko privede do oslabljenega dnevnega prirasta telesne mase, lezij na srcu, trebušni slinavki in skeletnih mišicah ter smrti.
What benefits of Clynav have been shown in studies?
Kakšne koristi je zdravilo Clynav izkazalo v študijah?
Protection lasts approximately three months after vaccination at average water temperature of 12 ±2 °C.
Zaščita pri povprečni temperaturi vode 12 ±2 °C traja približno tri mesece po cepljenju.
The immune system recognises these virus proteins as ‘foreign' and makes defences against them.
Imunski sistem virusne beljakovine prepozna kot „tujek“ in začne proti njim tvoriti protitelesa.
Clynav is a veterinary vaccine used in Atlantic salmon to protect them against pancreas disease caused by salmonid alphavirus subtype 3 (SAV3).
Clynav je cepivo za uporabo v veterinarski medicini, ki se uporablja pri atlantskem lososu za zaščito pred boleznijo trebušne slinavke, ki jo povzroča salmonidni alfavirus podtipa 3 (SAV3).
Six laboratory studies were conducted in fresh water and sea water to show how effective the vaccine was in protecting salmon from disease caused by SPDV.
V sladki in morski vodi so opravili šest laboratorijskih študij, s katerimi so dokazovali učinkovitost cepiva pri zaščiti lososa pred boleznijo, ki jo povzroča SPDV.
What is Clynav and what is it used for?
Kaj je zdravilo Clynav in za kaj se uporablja?
Vaccines work by ‘teaching' the immune system (the body's natural defences)
Cepiva delujejo tako, da imunski sistem (naravni obrambni mehanizem telesa) „naučijo“, kako naj se brani pred boleznijo.
The European Commission granted a marketing authorisation valid throughout the EU for Clynav on
Evropska komisija je dovoljenje za promet z zdravilom Clynav, veljavno po vsej Evropski uniji, izdala
For the full list of all side effects reported with Clynav, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Clynav, glejte navodilo za uporabo.
In case of accidental needle stick or self-injection, medical advice should be sought immediately and the package leaflet or label shown to the doctor.
V primeru nenamernega vboda z iglo ali samoinjiciranja nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
Why is Clynav approved?
Zakaj je bilo zdravilo Clynav odobreno?
It is not intended to provide practical advice on how to use Clynav.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Clynav is available as a solution for injection and can only be obtained with a prescription.
Zdravilo Clynav je na voljo v obliki raztopine za injiciranje, predpisovanje in izdaja zdravila pa je le na recept.
A main laboratory model study looked at the signs of pancreas disease in fish given Clynav compared with a dummy saline injection.
V glavni laboratorijski modelni študiji so preučevali znake bolezni trebušne slinavke pri ribah, ki so prejele zdravilo Clynav, v primerjavi z injekcijo fiziološke raztopine brez zdravilne učinkovine.
For practical information about using Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za praktične informacije o uporabi zdravila Clynav naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
For more information about treatment with Clynav, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Za več informacij o zdravljenju z zdravilom Clynav naj lastniki ali skrbniki živali preberejo navodilo za uporabo ali se posvetujejo z veterinarjem ali farmacevtom.
Clynav contains as active substance a DNA plasmid (a small piece of DNA) containing the genetic code for making salmon pancreas disease virus proteins.
Zdravilo Clynav kot zdravilno učinkovino vsebuje plazmidno DNK (majhen del DNK), ki vsebuje genetski zapis za proizvodnjo beljakovin virusa bolezni trebušne slinavke pri lososu.
How does Clynav work?
Kako zdravilo Clynav deluje?
Clynav salmon pancreas disease vaccine (recombinant DNA plasmid)
Clynav cepivo za bolezen trebušne slinavke pri lososu (rekombinantna plazmidna DNK)
Clynav contains a DNA plasmid which, once injected into fish, will lead to the production of salmon pancreas disease virus (SPDV) proteins.
Zdravilo Clynav vsebuje plazmidno DNK, ki po injiciranju v ribo sproži nastajanje beljakovin virusa bolezni trebušne slinavke pri lososu (SPDV).
How is Clynav used?
Kako se zdravilo Clynav uporablja?
The fate of the remainder is unknown.
Usoda preostanka ni znana.
This means that the risk that you develop a malignant disease in the future is slightly higher than for healthy people.
To pomeni, da je tveganje, da se pri vas v prihodnje razvije maligna bolezen, nekoliko višje kot pri zdravih ljudeh.
Date of first authorisation: 14/04/2004 Date of last renewal: 27/03/2009
Datum prve odobritve: 14/04/2004 Datum zadnjega podaljšanja: 27/03/2009
Less than a third of febrile events are associated with a documented infection.
Manj kot tretjina febrilnih dogodkov je povezanih z dokumentirano okužbo.
Patients less than 18 years of age.
Bolniki mlajši od 18 let.
* see descriptive section below.
* glej opisno poglavje spodaj.
Your doctor may decide that you should receive blood transfusions to improve your level of blood cells.
Vaš zdravnik se bo morda odločil, da boste prejemali transfuzije krvi za izboljšanje ravni vaših krvnih celic.
Their frequency varies widely, ranging from 2% to 21%.
Njihova pogostnost je zelo različna, v razponu od 2 % do 21 %.
At present there exists no experience on possible long-term consequences of this immunosuppression.
Trenutno ni izkušenj v zvezi z možnimi dolgotrajnimi posledicami te imunosupresije.
Your doctor will tell you how much LITAK you need and how often and when you have to inject yourself.
Vaš zdravnik vam bo povedal, koliko zdravila LITAK potrebujete in kako pogosto in kdaj si ga morate sami injicirati.
Your doctor may advise you about the possibility to store deep-frozen sperm (cryoconservation).
Vaš zdravnik vam bo morda svetoval o možnosti shranjevanja globoko zmrznjene sperme (kriokonservacija).
All patients were successfully treated with corticosteroids.
Vse bolnike so uspešno zdravili s kortikosteroidi.
Inject straight away.
Takoj injicirajte.
Repeated occurrence of malignant (cancerous) disease cannot be excluded.
Ponavljajočega se pojava maligne (rakave) bolezni ni mogoče izključiti.
The majority of deaths related to the medicinal product are due to infectious complications.
Večina smrti, povezanih z zdravilom, je posledica zapletov zaradi okužbe.
The origin of febrile events should be investigated by appropriate laboratory and radiologic tests.
Izvor febrilnih dogodkov je treba raziskati z ustreznimi laboratorijskimi in radiološkimi preiskavami.
Experience with patients older than 65 years is limited.
Izkušnje pri bolnikih, starejših od 65 let, so omejene.
Put the needle fully into the skin at an angle of about 45°, as shown in the picture.
Iglo vbodite v kožo do konca pod kotom približno 45°, kot je prikazano na sliki.
Your doctor will calculate your dose according to your body weight and explain the treatment schedule in detail.
Vaš zdravnik bo izračunal vaš odmerek na podlagi vaše telesne mase in vam podrobno razložil časovni razpored zdravljenja.
Check you have the right volume.
Preverite, da imate pravo prostornino.
The frequencies are defined as follows: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Pogostnosti so določene kot sledi: zelo pogosti (> 1/10), pogosti (> 1/100 do < 1/10), občasni (> 1/1.000 do < 1/100), redki (> 1/10.000 do <1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Unless fatal, indications were that most or all of these effects would be slowly reversible upon cessation of exposure.
Če niso bili smrtni, je za večino ali vse od teh učinkov kazalo, da bodo po prenehanju izpostavljanja počasi reverzibilni.
Find a comfortable, well-lit place and put everything you need where you can reach it.
Poiščite udoben, dobro osvetljen prostor in si pripravite vse, kar potrebujete, tako da bo v dosegu roke.
Before and during treatment with LITAK, you will have regular blood tests to check whether it is safe for you to continue with your treatment.
Pred zdravljenjem z zdravilom LITAK in med njim boste imeli redne preiskave krvi s katerimi bodo preverili ali je varno, da nadaljujete z vašim zdravljenjem.
Before you inject LITAK, you must do the following:
Pred injiciranjem zdravila LITAK morate narediti sledeče:
This section contains information on how to give an injection of LITAK.
To poglavje vsebuje podatke o tem, kako dati injekcijo zdravila LITAK.
Inject the liquid slowly and evenly for approximately one minute, always keeping the skin pinched.
Tekočino počasi in enakomerno injicirajte približno eno minuto, koža ves čas držite v kožni gubi.
Dose reduction and regular monitoring of the patient is required in such cases.
V takih primerih je potrebno znižanje odmerka in redno spremljanje bolnika.
The overall response rate was 97% with long-lasting remission, with 73% of patients staying in complete remission after four years follow-up time.
Celokupna stopnja odziva je bila 97 % z dolgotrajno remisijo, pri čemer je 73 % bolnikov doseglo popolno remisijo po štirih letih spremljanja.
Fatal outcome
Smrtni izid
Treatment of nausea with antiemetics is usually not necessary.
Zdravljenje slabosti z antiemetiki običajno ni potrebno.
(myelosuppression).
(mielosupresija).
The vials are for single use only.
Viale so namenjene samo enkratni uporabi.
Lipomed GmbH Hegenheimer Strasse 2 D-79576 Weil/Rhein Germany
Lipomed GmbH Hegenheimer Strasse 2 D-79576 Weil/Rhein Nemčija
Carcinogenesis/mutagenesis
Kancerogeneze/mutageneza
The peak risk is at 2 years after diagnosis with a median between 40 and 66 months.
Tveganje je najvišje po preteku 2 let od diagnoze z mediano med 40 in 66 meseci.
If not used immediately, in-use storage times and conditions are the responsibility of the user.
Če ga ne uporabite takoj, je za čas in pogoje shranjevanja pripravljene raztopine odgovoren uporabnik.
If severe toxicity occurs, the physician should consider delaying or discontinuing the therapy with the medicinal product until serious complications resolve.
Če se pojavi huda toksičnost, naj zdravnik razmisli o odložitvi ali ukinitvi zdravljenja z zdravilom, dokler resni zapleti niso razrešeni.
Your must not use LITAK if you are pregnant.
Zdravila LITAK ne smete uporabljati, če ste noseči.
Other medicines and LITAK
Druga zdravila in zdravilo LITAK
Deviations from the posology indicated above are not advised.
Odstopanja od zgoraj navedenega odmerjanja niso priporočljiva.
If you see blood in the syringe, remove the needle and re-insert it in another place.
Če v brizgi zagledate kri, iglo izvlecite in jo vbodite drugam.
If you had these symptoms prior to treatment with cladribine, tell your doctor about any change in these symptoms.
Če ste imeli te simptome pred začetkom zdravljenja s kladribinom, o kakršni koli spremembi simptomov obvestite zdravnika.